Orion - Company Announcement

150,000 Orion A-shares converted into B-shares

ORION CORPORATION      STOCK EXCHANGE RELEASE 4 JULY 2014 at 09.30
EEST

150,000 Orion A-shares converted into B-shares

In accordance with Section 3 of the Articles of Association of Orion
Corporation, 150,000 A-shares have been converted into 150,000 B-shares. The
conversion has been entered into the Trade Register on 4 July 2014.

The total number of shares in Orion Corporation is 141,257,828 which, after the
conversion, consists of 41,372,816 A-shares and 99,885,012 B-shares.


Orion Corporation


 Olli Huotari                Jari Karlson
 SVP, Corporate Functions    CFO






Publisher:
Orion Corporation
Communications
Orionintie 1A, FI-02200 Espoo, Finland
Homepage: www.orion.fi


Orion is a globally operating Finnish company developing pharmaceuticals and
diagnostic tests - a builder of well-being. Orion develops, manufactures and
markets human and veterinary pharmaceuticals, active pharmaceutical ingredients
and diagnostic tests. The company is continuously developing new drugs and
treatment methods. Pharmaceutical R&D focuses on central nervous system drugs,
oncology and critical care drugs, and Easyhaler® pulmonary drugs.

Orion's net sales in 2013 amounted to EUR 1,007 million and the company had
about 3,500 employees. Orion's A and B shares are listed on NASDAQ OMX Helsinki.

[HUG#1813912]